Biotech Spikes After Settling Debate Over Its Seizure Medicine

GW Pharmaceuticals (GWPH) settled a debate Tuesday on whether its cannabinoid seizure drug, Epidiolex, is only effective in a combination — prodding shares to an eight-month high on successful data.

XAutoplay: On | OffBy the closing bell on the stock market today, GW soared by 11.1% to 127.54.

The firm is testing Epidiolex in patients with what's known as Lennox-Gastaut syndrome, a type of epilepsy that affects children. Prior tests were in patients already receiving an approved drug...

What feeling does this article give you?

#hashtags to follow:

GW Pharmaceuticals [+]    GWPH [+]    Epidiolex [+]    XAutoplay [+]    Lennox [+]    Gastaut [+]   

More #news: